Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Poolbeg Pharma Ltd. ( (GB:POLB) ) has shared an update.
Poolbeg Pharma has announced the granting of a patent in Korea for its POLB 001, a p38 MAP kinase inhibitor, which is used in treating severe influenza and has potential applications in cancer immunotherapy-induced Cytokine Release Syndrome. This patent, valid until December 2038, strengthens Poolbeg’s global intellectual property portfolio, enhancing the value and attractiveness of POLB 001 to potential partners and stakeholders, and aligns with the company’s strategy to address significant unmet medical needs globally.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs, with a strong and growing portfolio of development assets.
YTD Price Performance: -59.86%
Average Trading Volume: 2,321,205
Technical Sentiment Consensus Rating: Buy
See more insights into POLB stock on TipRanks’ Stock Analysis page.